Last update: Nov. 25, 2014
Minimal risk for breastfeeding and infant.
This is a Heparin with low molecular weight.
At latest update, relevant published data on its excretion into breast milk were not found.
The high molecular weight of the so-called Standard or non-fragmented Heparin and others called low weight Heparins makes that excretion into breast milk very unlikely.
There is published evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin.
There is scientific proof on the lack of excretion of Dalteparin into breast milk.
In addition, Heparin derived drugs are inactivated in the gut and they are not absorbed at all, hence, oral bioavailability is nil.
The risk of Heparin-induced Thrombocytopenia and Osteoporosis is lower with low weight Heparin among treated adults.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM